首页> 美国卫生研究院文献>BMC Health Services Research >Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
【2h】

Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register

机译:降低2型糖尿病和风险相关LDL胆固醇患者的降脂药物处方:瑞典国家糖尿病登记系统对指南依从性的全国性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundManagement of type 2 diabetes mellitus (T2DM) encompasses intensive glycaemic control, along with treatment of comorbidities and complications to handle the increased risk of cardiovascular disease (CVD). Improved control of LDL-cholesterol (LDL-C) with lipid-lowering medications is associated with reduced CVD risk in T2DM patients. Thus, treatment guidelines recommend lipid-lowering medications for T2DM patients with LDL-C above risk-associated thresholds. This study aimed to assess healthcare provider adherence to guidelines regarding lipid-lowering medication prescription among T2DM patients and to analyse factors associated with lipid-lowering medication prescription.
机译:背景2型糖尿病(T2DM)的管理包括严格的血糖控制以及合并症和并发症的治疗,以应对增加的心血管疾病(CVD)风险。用降脂药物改善对LDL-胆固醇(LDL-C)的控制可降低T2DM患者的CVD风险。因此,治疗指南建议LDL-C高于风险相关阈值的T2DM患者使用降脂药物。这项研究旨在评估医疗保健提供者对T2DM患者中降脂药物处方指南的遵守情况,并分析与降脂药物处方相关的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号